Electrophysiologic Measures of Treatment Response in Alzheimer Disease - Full Text View

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

This study has been completed.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018278

Purpose

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Condition	Intervention	Phase
Alzheimer Disease	Drug: Aricept Drug: Exelon Drug: Nicoderm Patch	Phase IV

Genetics Home Reference related topics:

Alzheimer disease

MedlinePlus related topics:

Alzheimer's Disease

Drug Information available for:

Donepezil E 2020 Rivastigmine SDZ-ENA 713 Nicotine polacrilex Nicotine tartrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study

Official Title:	Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 1998
Estimated Study Completion Date:	September 2001

Eligibility

Ages Eligible for Study:	55 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018278

Locations


United States, California
	Department of Veterans Affairs
	San Diego, California, United States, 92161

Sponsors and Collaborators

Department of Veterans Affairs

Investigators


Investigator:	Vincente Iragui, M.D., Ph.D

Investigator:	Shuanna Morris, Ph.D.

More Information

Study ID Numbers:	AGCG-004-98S
First Received:	July 3, 2001
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00018278
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Nicotine polacrilex

Rivastigmine

Alzheimer Disease

Central Nervous System Diseases

Brain Diseases

Neurodegenerative Diseases

Cognition Disorders

Delirium, Dementia, Amnestic, Cognitive Disorders

Mental Disorders

Nicotine

Donepezil

Dementia

Delirium

Additional relevant MeSH terms:

Nervous System Diseases

Tauopathies

ClinicalTrials.gov processed this record on December 03, 2008